Emma Griffin Author
Subjects of specialization
Affiliation
Hydrobiology ,Physiology of Marine Organisms,Fisheries Biology and Management,Marine Biology ,Marine Chemistry
Queen Mary University of London, United Kingdom
Emma Griffin works at the Queen Mary University of London, United Kingdom Specialized in Hydrobiology, Hydrology, Marine Conversation, Marine Biology, Marine Chemistry, Physiology of Marine Organisms, Fisheries Biology and Management.
Editorial Subscription
Author(s): Emma Griffin
Cytarabine is the first anti-cancer medicine of marine origin to be commercially accessible. It's a pyrimidine nucleoside analogue that serves as a cytotoxic medication that targets the cell cycle specifically. It is most active during cell division's S phase, when the cells are undertaking DNA synthesis. The US Food and Drug Administration (FDA) approved cytarabine, which was marketed under the brand name Cytosar-U®. A staple medicine in the treatment of acute myeloid leukaemia, acute lymphoblastic leukaemia, and chronic myelogenous leukaemia is Cytosar-U®. Since then, further anti-cancer compounds derived from marine sources have been accessible. For example, the liposomal formulation CPX-351 (Vyxeos®) contains a 5:1 ratio of cytarabine and daunorubicin. When CPX-3... view moreĀ»